CLCS Projected Dividend Yield
Cell Source Inc ( OTCBB : CLCS )Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. Co.'s main prospective product is its patented Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Co.'s target indications include: lymphoma, leukemia and multiple myeloma through the facilitation of stem cell transplantation acceptance, treatment of end stage kidney disease and other non-malignant organ diseases through improved organ transplantation, and treating a variety of cancers and non-malignant diseases. 20 YEAR PERFORMANCE RESULTS |
CLCS Dividend History Detail CLCS Dividend News CLCS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |